19(T2)28z1xx CAR T cells for Waldenstrom Macroglobulinemia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Waldenstrom Macroglobulinemia+13 More
19(T2)28z1xx CAR T cells - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The goal is to find the highest dose that causes few or mild side effects. Future trials will test if it is effective in treating relapsed/refractory B-cell cell cancers.

Eligible Conditions
  • Waldenstrom Macroglobulinemia
  • Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Lymphoma, Non-Hodgkin
  • Lymphoma
  • B-Lymphocytes
  • Chronic Lymphocytic Leukemia (CLL)
  • Primary Central Nervous System Lymphoma (PCNSL)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Waldenstrom Macroglobulinemia

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 2 years

2 years
overall response rate (ORR)
28 days post infusion
Recommended Phase II Dose (RP2D)

Trial Safety

Safety Progress

1 of 3

Other trials for Waldenstrom Macroglobulinemia

Trial Design

1 Treatment Group

19(T2)28z1xx CAR T cells
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: 19(T2)28z1xx CAR T cells · No Placebo Group · Phase 1

19(T2)28z1xx CAR T cells
Drug
Experimental Group · 1 Intervention: 19(T2)28z1xx CAR T cells · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

TakedaIndustry Sponsor
1,108 Previous Clinical Trials
4,042,825 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,821 Previous Clinical Trials
584,317 Total Patients Enrolled
Jae Park, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
11 Previous Clinical Trials
367 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have adequate pulmonary function as assessed by pulse oximetry.
You have relapsed disease after 2 or more chemoimmunotherapies with at least one containing an anthracycline and CD20 directed therapy.
The tumor must be histologically confirmed as a large B cell lymphoma.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: October 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.